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930Publication Bias in Blood and Marrow Transplantation
Mahwash Saeed,1 Kristjan Paulson,1,2 P. Lambert,2 David Szwajcer,1,2,3 Matthew Seftel1,2,3Only a small proportion of abstracts lead to full publication. Abstracts with ‘‘positive’’ results are more likely
to be published than other abstracts, leading to publication bias. To date, this issue has not been examined in
the blood and marrow transplantation (BMT) literature. We hypothesized that because BMT centers are of-
ten based at academic centers, the proportion of abstracts leading to publication will be high. All abstracts
presented at the Canadian Blood and Marrow Transplant Group biannual meetings in 2002, 2004, and 2006
were reviewed and categorized by study type, funding source, single-center or multicenter study, form of
presentation, and positive or negative results, using the authors’ definitions. To determine publication,
each reference was searched on multiple databases (MEDLINE, EMBASE, Web of Science, and CINAHL)
by first, second, and final author names. Two authors performed abstract categorization and searching,
and disagreements were resolved by consensus. Of the 141 abstracts reviewed, only 43 were published
(30.4%). Twenty-one studies were published from 2002 (36.8%), compared with 12 from 2004 (24.0%)
and 10 from 2006 (29.4%) (P 5 .35). Neither positive results nor the number of involved centers were
associated with the likelihood of publication. Clinical studies (retrospective or prospective) were more likely
to be published than nonclinical studies (P5.014). Funded studies and oral presentations were more likely to
be published (P 5 .009 and .004, respectively). A low rate of publication is seen in the field of BMT. Studies
with clinical outcomes, externally funded studies, and studies presented orally were more likely to be pub-
lished. However, there was no publication bias in favor of studies with positive results. Publication bias should
be evaluated further at larger BMT meetings, and efforts should be made to encourage full publication of
scientific abstracts.
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In thebiomedical literature, a largeproportionof ab-
stracts presented at scientificmeetings fail to achieve full
publication within 5 years of abstract presentation [1-3].
Publication bias refers to the tendency of authors to
submit, and journals to accept, material for publication
based on the strength or direction of study results [4].
Dissemination of results from medical research in
the form of full publication is a key requirement of
evidence-basedmedicine, and improving the availability1Section of Hematology/Oncology, Department of Inter-
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education, accelerate further research, or prevent
further redundant research [1,2]. Although meeting
abstracts may be available for review in the form of
journal supplements or meeting proceedings, they
may be difficult to obtain and present limited
information, and there may be inconsistencies between
the meeting abstracts and later publications [3].
Certain variables have been shown to be associated
with successful publication of manuscripts. Numerous
previous analyses have suggested that abstracts in basic
science, oral presentations, randomized controlled
trials, and studies with ‘‘positive’’ results are more
likely to be published in full [2,5,6]. Nonpublication
of results can lead to publication bias; as a result,
systematic reviews, meta-analyses, or practice guide-
lines will tend to overestimate treatment effects by
basing conclusions on a disproportionate number of
positive studies [1,3,6].
The issue of publication bias has not yet been ad-
dressed in the blood and marrow transplantation
(BMT) literature. We hypothesized that because
BMT centers in Canada are based at large, academic
centers involved in a highly specialized and relatively
novel discipline, the proportion of abstracts leading
Biol Blood Marrow Transplant 17:930-934, 2011 931Publication Bias in Blood and Marrow Transplantationto publication will be high. The present study had 3
objectives: (1) to establish a rate of publication for all
abstracts presented at a Canadian BMT conference,
(2) to measure time to publication for each abstract,
and (3) to analyze for any specific predictors of
publication.METHODS
The Canadian Blood and Marrow Transplant
Group (CBMTG) is a national body with a mission
to provide leadership and promote excellence in pa-
tient care, research, and education in the field of
BMT. Toward this end, the CBMTG represents
BMT issues to government agencies, health care orga-
nizations, and the public; has established a clinical tri-
als network helping clinicians from different centers to
collaborate on studies; and provides a platform for new
studies to be presented in the form of research meet-
ings. The biennial CBMTG meeting has both educa-
tional and research objectives. CBMTG members are
invited to submit abstracts on basic science or clinical
research relevant to the field of BMT. The CBMTG
Executive Committee nominates an independent ab-
stract review panel for each meeting. The review panel
nominates the leading abstracts for oral presentation,
while the remainder are presented in poster format.
All abstracts submitted for the CBMTG 2002,
2004, and 2006 biennial meetings were obtained for
review directly from the CBMTG head office in
Vancouver, BC, Canada. Each abstract was evaluated,
and information on the following variables was re-
corded: study type (retrospective or prospective clinical,
basic science, case report, translational research, or
other types of research), funding source (combining
either industry or nonindustry sources), form of presen-
tation (poster vs oral), single-center or multi-center
involvement, and positive or negative results, using
the authors’ definitions and interpretation of results.
To accurately define the authors’ definitions and
interpretation of results, we used the same criteria as
in the Cochrane Review on publication bias and iden-
tified two definitions of positive [6]. The first of these
defines positive studies as those that showed a statisti-
cally significant result in the direction of, or a stated
preference for, the experimental treatment compared
with the control treatment. The second defines
positive results as those showing statistically signifi-
cant results or a preference for either treatment arm
compared with neutral results.
To determine the publication status of each
abstract, we performed searches for each reference on
4onlinedatabases:MEDLINE,EMBASE,WebofSci-
ence, and CINAHL. These searches were performed
between November 1, 2009, and January 11, 2010.
Each reference was searched by first, second, and last
author names. If full publication was found, then dateof acceptance by the journal was recorded. Evaluation,
categorization, and searches were performed by 2 of 3
authors (Mahwash Saeed, Kristjan Paulson, Matthew
Seftel) for each abstract, and any discrepancieswere dis-
cussed and resolved by consensus among the 3 authors
performing the review. Interrater reliability for each
variable was measured using the k statistic.
Comparisons of rate of publication based on study
type, funding source, single-center or multicenter in-
volvement, and positive or negative results were done
using the c2 test, with a P value\.05 considered signif-
icant. Time to publication for all abstracts eventually
published was analyzed using the Kaplan-Meier
method. All results were analyzed using SPSS version
17.0 for Macintosh (SPSS, Chicago, IL).RESULTS
A total of 141 abstracts were submitted for the
2002, 2004, and 2006 CBMTG meetings. All 141 ab-
stracts were accepted for presentation, and all were
available for further review (Table 1). A total of 119
abstracts were presented in poster form, and 22 ab-
stracts were presented orally. During the study period,
43 abstracts (30.4%) achieved full publication. The
median time from presentation to publication was
631 days, or 20.7 months (range, 5.3 months before
the meeting to 91.2 months [7.6 years] after the meet-
ing). Although most abstracts were published within
the first year of the meeting, 5 (11.6%) were published
more than 4 years after initial presentation (Figure 1).
Interrater reliability for each evaluated variable, as
measured by the k statistic, was as follows: type of
study, 0.80; positive versus negative study, 0.25;
single-center versus multicenter study, 0.79; funding
source, 0.47.
Of the 57 abstracts accepted in 2002, 21 (36.8%)
were published, compared with 12 of 50 (24%) in
2004 and 10 of 34 (29.4%) in 2006 (P 5 .35). Clinical
studies (of either retrospective or prospective design)
were more likely to be published than nonclinical stud-
ies (38.4% vs 18.2%; P5 .014). Neither the number of
centers involved in the abstract nor the presence of
positive results was associated with increased likeli-
hood of publication. Studies that declared a source of
funding were more likely to be published (P 5 .009).
Finally, oral presentations were more likely to be
published than posters (59.1% vs 25.2%; P 5 .004).
At the time of study completion, only 44 months
had elapsed since the 2006 CBMTG meeting, com-
pared with 68 months for the 2004 meeting and 92
months for the 2002 meeting. To minimize potential
bias against the 2006 meeting with the shorter
follow-up time, we censored any abstracts published
44 months after both the 2002 and 2004 meetings. In
this secondary analysis, we removed ‘‘published’’ status
Table 1. Rate of Publication for the 141 Abstracts Presented
at the CBMTG Meetings
Predictor of Abstract
Publication
Number
of Abstracts
Rate of
Publication
P
Value*
Form of presentation
Oral 22 13/22 (59.1%) .004
Poster 119 30/119 (25.2%)
Funded study†
Funded 10 7/10 (70.0%) .009
Nonfunded or not specified 131 36/131 (27.5%)
Study type
Clinical 86 33/86 (38.4%) .014
Nonclinical 55 10/55 (18.2%)
Number of centers involved
Single 119 33/119 (27.7%) .130
Multiple 22 10/22 (45.5%)
Study results
Positive 53 20/53 (37.7%) .186
Negative 88 23/88 (26.1%)
Year of presentation
2002 57 21/57 (36.8%) .350
2004 50 12/50 (24.0%)
2006 34 10/34 (29.4%)
*c2 test.
†Source of funding was either government or industry.
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44-month study period. Clinical studies and oral
presentation were no longer statistically significant
predictors of publication (P 5 .092 and .072, respec-
tively). Source of funding remained a statistically sig-
nificant predictor of publication (P 5 .001), whereas
positive study results and year of publication remained
nonsignificant (P 5 .436 and .182, respectively).DISCUSSION
We theorized that abstracts from a Canadian BMT
meeting would enjoy a higher-than-average rate of
publication, given that BMT centers in Canada are
affiliated with large academic centers and the BMTFigure 1. Cumulative rate of publication. Of the 141 abstracts studied,
43 (30.4%) achieved full publication. The median time from presentation
to publication was 631 days (1.7 years), with a range of 150 days before
the meeting to 2774 days (7.6 years) after the meeting. Five abstracts
(11.6%) were published more than 4 years after initial presentation.meeting is attended primarily by health professionals
with university affiliations. However, we found a low
publication rate at the CBMTG meeting, similar to
that for other medical specialties. Table 2 compares
the current studywith studies in other biomedical areas.
Our findings and those from other medical special-
ties from both national and international meetings
suggest that a substantial number of scientific studies
exist only in abstract form. These unpublished studies
may contain valuable information for clinicians, re-
searchers, and policymakers [7]. Clinical research
with negative results may prevent repetition of a simi-
larly futile or even harmful intervention. Based on fully
published papers, researchers may be prompted to
re-evaluate their hypotheses regarding a study
intervention or disease mechanisms. Conversely,
prompt diffusion of positive research by full publica-
tion carries the potential of immediate benefit to
patients, other researchers, and policymakers.
Low publication rates of meeting abstracts cannot
be attributed entirely to rejectionbypeer-reviewed jour-
nals, given that a significant proportion of unpublished
research is never even submitted for consideration by
journals [5,8]. Surveys of authors of nonsubmitted or
noncompleted studies cite low priority, anticipated
rejection, and lack of time and funding as reasons
for nonsubmission [1,7]. It is also plausible that some
of the abstracts presented at the CBMTG meeting
might have been deemed of sufficiently low quality
or impact to deter the investigators from publishing
their findings in full. The specific reasons for
nonsubmission within the BMT community were not
evaluated in the present study, and we recommend
that future studies examine this question.
We did not find that positive studies were more
likely to be published than negative or null ones;
thus, we were unable to demonstrate publication bias
in favor of positive studies. The absence of publication
bias in the present study may be a true finding, in
which case, the CBMTG investigators should beTable 2. Rate of Full Publication of Abstracts for Selected
Medical Disciplines
Gastroenterology 69.8%
Medical oncology 66.7%
Sports medicine 56.5%
Pediatrics 59.1%
General surgery 53.7%
Orthopedic surgery 50.7%
Obstetrics 50.0%
General internal medicine 47.9%
Rheumatology 40.5%
Anesthesiology 32.2%
Otolaryngology 32.1%
BMT (present study) 30.4%
Trauma/burns 26.2%
Emergency medicine 10.1%
Pediatric surgery 11.1%
Radiology 8.6%
Data derived from Scherer et al. [6]. Abstracts were presented at either
national or international meetings.
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less of the direction of their results. However, other
factors also might have contributed to our findings, in-
cluding our relatively small sample size, the high num-
ber of observational studies without clearly delineated
positive or negative endpoints, and the study period,
which might have missed studies published after the
date of final analysis in January 2010 (44 months after
the 2006 meeting).
The reviewers’ poor agreement in terms of whether
certain abstracts represented a positive study or
a negative study merits further discussion. There was
relatively poor interrater reliability for the positive/
negative coding system (k 5 0.25). We believe that
this is due to weaknesses in the wording and structure
of the abstracts, given that many of them did not ad-
dress a specific hypothesis or provide a definite outline
on the researcher’s study goals. Nonetheless, all dis-
agreements were discussed and resolved by consensus,
with all 3 reviewers re-examining and discussing each
abstract. We believe that this consensus approach was
able to overcome the initially low interrater reliability.
In the present study, other predictors for full pub-
lication of abstracts were similar to known predictors,
with the exception that clinical research abstracts were
more likely to be published than basic science research
abstracts. We found a significant association between
full publication and oral presentation, clinical studies,
and funded research. The interrater reliability for
funding source was also low, however. On subsequent
discussion, we found that one of the 3 reviewers had of-
ten found the funding source in the fully published pa-
per, whereas the other 2 reviewers, who had much
better interrater agreement, relied solely on the ab-
stract’s funding declaration. This inherently biased
this variable toward abstracts that reached full publica-
tion and was likely a spurious result. However, it does
suggest that a more stringent structure for abstracts
should followed when submitting to a research meet-
ing, such that any funding source or conflict of interest
is made clear at the abstract level.
From a methodological standpoint, our results
should offer some assistance to future research into
the issue of publication bias in the BMT literature.
First, all published studies were included in the
National Library of Medicine’s PubMed database,
suggesting that, at least in North American BMT
research, the use of other reference databases (e.g.,
EMBASE, CINAHL, Web of Science) is superfluous.
Second, the majority of abstracts (88.6%) were
published within 4 years from initial presentation, sug-
gesting that for accuracy, investigators should allow at
least a period of 4-5 years after a scientific meeting
before assessing publication rates. These results are
consistent with previous studies demonstrating that
.80% of successfully published abstracts will reach
this phase within 36 months [6].Our study had several limitations. The sample size
was small, and our focus was on a national, rather than
international, research meeting. Furthermore, we are
only able to comment on abstracts published before
January 11, 2010, and abstracts presented at the 2006
meeting may still be in press at the time of our study
analysis. This was addressed with our censored analysis,
which altered the significance of 2 of our study variables
but did not change our finding of a lack of publication
bias in favor of positive studies. Finally, our ability to
determine whether abstract results were positive or
negative was limited, as reflected by the poor k value
for this variable. Nonetheless, this study is the first to
evaluate publication bias in the specialized area of
BMT, and hopefully will serve as a basis for further
research into publication bias in the BMT literature.
The existence of clinical trial registries andmanda-
tory publishing of results are reasonable avenues to en-
sure that clinicians, policymakers, and reviewers have
ready access to study results. In 2004, the International
Committee of Medical Journal Editors made trial reg-
istration at or before patient enrollment a mandatory
condition for consideration of publication. The policy
of mandatory registration has greatly increased the
number of trials registered and also provides publicly
available information regarding the existence and de-
sign of clinical trials [9]. This expectation should be
further extended to research outside the realm of clin-
ical trials, such as observational studies and systematic
reviews, given that dissemination of the results of these
types of studies may be equally important [10].
Inconclusion,we found that themajorityof abstracts
presented at a national BMTmeeting went unpublished
during our study period. Such a deficiency is of great im-
portance in the area of BMT, in which interventions are
often associated with high toxicity, enormous complex-
ity, and great financial expense.We did not find publica-
tion bias in favor of positive results, however. Further
research is needed to establish whether publication bias
exists at larger, international BMTmeetings.ACKNOWLEDGMENTS
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